Septerna (SEPN) closed at $41.67 on November 16, 2026, down 2.2% from the previous close, on volume of 360,711 shares (30-day average 420,468).
Data as of November 16, 2026.
No headlines found.
Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results
Globe Newswire (Mon, 9-Nov 4:01 PM ET)
Globe Newswire (Wed, 4-Nov 8:00 AM ET)
Septerna to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 8:00 AM ET)
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 10-Sep 4:00 PM ET)
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
Globe Newswire (Tue, 25-Aug 8:00 AM ET)
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Septerna trades on the NASDAQ stock market under the symbol SEPN.
As of November 16, 2026, SEPN stock price declined to $41.67 with 360,711 million shares trading.
SEPN has a beta of 0.21, meaning it tends to be less sensitive to market movements. SEPN has a correlation of 0.00 to the broad based SPY ETF.
SEPN has a market cap of $1.98 billion. This is considered a Small Cap stock.
Last quarter Septerna reported $19 million in Revenue and -$.57 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.14.
The top ETF exchange traded funds that SEPN belongs to (by Net Assets): VTI, IWM, XPH, VXF, FYC.
SEPN has outperformed the market in the last year with a return of +116.6%, while the SPY ETF gained +11.2%. However, in the most recent history, SEPN shares have underperformed the stock market with its stock returning -7.7% in the last 3 month period and -5.3% for the last 2 week period, while SPY has returned -4.6% and -2.1%, respectively.
SEPN support price is $40.52 and resistance is $44.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SEPN shares will trade within this expected range on the day.